Amgen Inc. $AMGN Shares Purchased by Sumitomo Mitsui Financial Group Inc.

Sumitomo Mitsui Financial Group Inc. lifted its position in shares of Amgen Inc. (NASDAQ:AMGN) by 7.8% during the third quarter, according to its most recent Form 13F filing with the SEC. The institutional investor owned 75,779 shares of the medical research company’s stock after purchasing an additional 5,457 shares during the period. Sumitomo Mitsui Financial Group Inc.’s holdings in Amgen were worth $21,385,000 at the end of the most recent reporting period.

Other large investors have also recently made changes to their positions in the company. Legacy Investment Solutions LLC purchased a new stake in Amgen in the second quarter valued at approximately $27,000. Evelyn Partners Investment Management LLP purchased a new stake in Amgen in the 2nd quarter valued at $32,000. Howard Hughes Medical Institute purchased a new position in Amgen during the 2nd quarter worth $32,000. Quaker Wealth Management LLC increased its stake in Amgen by 200.0% in the second quarter. Quaker Wealth Management LLC now owns 120 shares of the medical research company’s stock valued at $34,000 after purchasing an additional 240 shares during the period. Finally, Cloud Capital Management LLC purchased a new stake in shares of Amgen in the third quarter valued at about $34,000. 76.50% of the stock is owned by institutional investors and hedge funds.

Amgen News Roundup

Here are the key news stories impacting Amgen this week:

• Positive Sentiment: Amgen hit an all-time intraday high, reflecting strong investor demand and momentum that likely supported upward price pressure earlier in the session. Amgen stock hits all-time high
• Positive Sentiment: Amgen is featured in dividend-stock roundup articles, which can attract long-term income-focused buyers and support demand for shares given its yield and payout profile. Got $10,000? Put It in These Dividend Stocks Now
• Neutral Sentiment: Commentary pieces note Amgen has outpaced the Dow over the past year, providing a positive performance backdrop — but analysts remain cautious, suggesting upside may be tempered by valuation and execution risks. Is Amgen Stock Outperforming the Dow?
• Neutral Sentiment: Legislative risk: S.3847 (Stop Corporate Inversions Act of 2026) was flagged as potentially relevant to multinationals including AMGN; the bill would tighten rules around inversion tax treatment — a longer-term policy item to monitor but not an immediate earnings driver. Stop Corporate Inversions Act of 2026
• Neutral Sentiment: Reported spikes in short interest appear in the feed but show zero shares/NaN in the figures — this looks like a data or reporting error rather than a meaningful change in positioning; still worth checking official exchange short-interest releases for confirmation.
• Negative Sentiment: A small institutional holder (Bradley Foster & Sargent) trimmed its position (~1,336 shares), a minor selling signal that may slightly contribute to sell-side flow but is not materially large versus Amgen’s market cap and average volume. Bradley Foster & Sargent Inc. CT Sells 1,336 Shares

Wall Street Analyst Weigh In

A number of equities analysts recently issued reports on AMGN shares. Royal Bank Of Canada raised their price target on Amgen from $335.00 to $360.00 and gave the stock an “outperform” rating in a report on Wednesday, February 4th. Leerink Partners increased their price objective on Amgen from $305.00 to $355.00 and gave the stock an “outperform” rating in a research report on Wednesday, February 4th. HSBC reiterated a “buy” rating and issued a $425.00 target price on shares of Amgen in a research note on Wednesday, December 10th. Deutsche Bank Aktiengesellschaft boosted their target price on Amgen from $285.00 to $295.00 and gave the company a “hold” rating in a report on Thursday, February 5th. Finally, Erste Group Bank raised Amgen from a “hold” rating to a “buy” rating in a report on Friday, December 5th. One analyst has rated the stock with a Strong Buy rating, fifteen have given a Buy rating, eleven have issued a Hold rating and two have assigned a Sell rating to the company’s stock. According to data from MarketBeat, the stock has an average rating of “Moderate Buy” and a consensus target price of $351.76.

Amgen Stock Performance

Shares of AMGN stock opened at $379.33 on Friday. The company has a current ratio of 1.14, a quick ratio of 0.90 and a debt-to-equity ratio of 5.78. Amgen Inc. has a 12-month low of $261.43 and a 12-month high of $387.49. The company has a market cap of $204.48 billion, a price-to-earnings ratio of 26.66, a price-to-earnings-growth ratio of 3.81 and a beta of 0.46. The stock has a 50 day simple moving average of $347.68 and a 200-day simple moving average of $318.76.

Amgen (NASDAQ:AMGN) last released its quarterly earnings data on Tuesday, February 3rd. The medical research company reported $5.29 earnings per share (EPS) for the quarter, topping the consensus estimate of $4.76 by $0.53. The firm had revenue of $9.87 billion during the quarter, compared to analysts’ expectations of $9.46 billion. Amgen had a return on equity of 148.37% and a net margin of 20.98%.Amgen’s revenue was up 8.6% compared to the same quarter last year. During the same quarter in the prior year, the business posted $5.31 earnings per share. Amgen has set its FY 2026 guidance at 21.600-23.000 EPS. On average, equities analysts forecast that Amgen Inc. will post 20.62 EPS for the current year.

Amgen Increases Dividend

The business also recently disclosed a quarterly dividend, which will be paid on Friday, March 6th. Investors of record on Friday, February 13th will be paid a $2.52 dividend. This represents a $10.08 annualized dividend and a dividend yield of 2.7%. This is a positive change from Amgen’s previous quarterly dividend of $2.38. The ex-dividend date is Friday, February 13th. Amgen’s dividend payout ratio (DPR) is 70.84%.

About Amgen

Amgen Inc (NASDAQ: AMGN) is a global biotechnology company founded in 1980 and headquartered in Thousand Oaks, California. The company focuses on discovering, developing, manufacturing and delivering human therapeutics that address serious illnesses. Amgen’s work centers on biologic medicines derived from cellular and molecular biology, with an emphasis on translating advances in human genetics and protein science into therapies for patients.

Amgen’s commercial portfolio has historically included biologics used in oncology, supportive care, nephrology, bone health and cardiovascular disease.